Positive Phase III data for ublituximab in relapsing multiple sclerosis

In the ULTIMATE I and II studies, the anti-CD-20 monoclonal antibody was shown to be associated with a statistically significant reduction in annualised relapse rate over 96 weeks (less than 0.10 in both), with a larger reduction than teriflunomide [no specific results reported].

Source:

Biospace Inc.